The Center of Excellence of NANOtechnology for Treatment, Understanding, and Monitoring of Cancer (NANO-TUMOR) has been established to perfect a practical nanotechnology base to diagnose, treat, and monitor cancers. Our goal is the development, of a multi-functional """"""""smart mothership"""""""" platform that will: (1) evade the reticuloendothelial system and immune system, while attaching specifically to the tumor and its vasculature;(2) assemble a multi-functional complex at the tumor site;(3) deliver payloads of both nanosensors and therapeutics that are activated in situ. The NANO-TUMOR Center has brought together a team of investigators from the University of California, San Diego, Santa Barbara, Irvine, and Riverside campuses, the Burnham Institute and NanoBioNexus. The NANO-TUMOR Center research program is comprised of six interacting projects, each utilizing newly developed and unique technologies that when integrated together will lead to the realization of our goal. The six projects focus on (1) the production of tumor-targeted, non-toxic nanoparticles, (2) the development of a nanoporous micro-platform carrying nanosensors, imaging and therapeutic agents, (3) the creation of tumor-directed amplification systems for sensing and drug delivery, (4) the construction of devices for tumor molecule purification and characterization at a nanoscale level, (5) the application of new computational methods for longitudinal monitoring and analyses of tumor progression and response to therapy, and (6) the in situ assembly and delivery of targeted therapeutics with a smart nanotechnology platform. The Center has been organized using a novel, engineering-type decision and workflow model: Multiple approaches have been proposed to address each project, with go/no go decisions made based on achievement of milestones. The NANOTUMOR project leaders have previously founded more than 20 successful biotechnology companies, with a total market value of over two billion dollars, evidence of their ability to move discoveries to useful applications in the marketplace. The intent of the NANO-TUMOR Center to develop clinically useful platforms is also demonstrated by the strategic role that clinicians from the UCSD Cancer Center, and participants from major corporations (General Electric, Honeywell, Nanogen, Enterprise) will play in evaluating the research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S (O1))
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Internal Medicine/Medicine
Schools of Medicine
La Jolla
United States
Zip Code
Schutt, Carolyn; Ibsen, Stuart; Zahavy, Eran et al. (2017) Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin. Pharm Res 34:2025-2035
Heineck, D P; Lewis, J M; Heller, M J (2017) Electrokinetic device design and constraints for use in high conductance solutions. Electrophoresis 38:1475-1482
Manouchehri, Sareh; Ibsen, Stuart; Wright, Jennifer et al. (2016) Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol 5:27-35
Sandoval, Sergio; Mendez, Natalie; Alfaro, Jesus G et al. (2015) Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform. J Biomed Opt 20:88003
Goodwin, Andrew P; Nakatsuka, Matthew A; Mattrey, Robert F (2015) Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:111-23
Campbell, Diahnn F; Saenz, Rebecca; Bharati, Ila S et al. (2015) Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. Breast Cancer Res 17:48
Ortac, Inanc; Simberg, Dmitri; Yeh, Ya-san et al. (2014) Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Lett 14:3023-32
Sonnenberg, Avery; Marciniak, Jennifer Y; Rassenti, Laura et al. (2014) Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem 60:500-9
Saenz, R; Messmer, B; Futalan, D et al. (2014) Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. Mol Immunol 57:191-9
Sonnenberg, Avery; Marciniak, Jennifer Y; Skowronski, Elaine A et al. (2014) Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis 35:1828-36

Showing the most recent 10 out of 146 publications